Overview

  • Product nameAnti-Tau (phospho S214) antibodySee all Tau primary antibodies ...
  • Description
    Rabbit polyclonal to Tau (phospho S214)
  • Tested applicationsWB, IHC-P, ICCmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat, Goat, Cow, Chimpanzee
  • Immunogen

    Synthetic peptide conjugated to KLH derived from within residues 200 - 300 of Human Tau, phosphorylated at S214.

    (Peptide available as ab19123.)

  • Positive control
    • This antibody gave a positive signal in Hela whole cell lysate. It also gave a positive result in FFPE human Alzhiemer hippocampus tissue sections

Properties

Applications

Our Abpromise guarantee covers the use of ab10891 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/250. Detects a band of approximately 90 kDa (predicted molecular weight: 79 kDa).Can be blocked with Human Tau (phospho S214) peptide (ab19123).
IHC-P Use at an assay dependent concentration.
ICC Use at an assay dependent concentration. PubMed: 22003387

Target

  • FunctionPromotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
  • Tissue specificityExpressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.
  • Involvement in diseaseNote=In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU).
    Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.
    Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.
    Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.
    Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104, 260540]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.
  • Sequence similaritiesContains 4 Tau/MAP repeats.
  • Developmental stageFour-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain.
  • DomainThe tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.
  • Post-translational
    modifications
    Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK: CDK1, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis.
    Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.
    Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.
  • Cellular localizationCytoplasm > cytosol. Cell membrane. Cytoplasm > cytoskeleton. Cell projection > axon. Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.
  • Information by UniProt
  • Database links
  • FormThere are 9 isoforms produced by alternative splicing.
  • Alternative names
    • AI413597 antibody
    • AW045860 antibody
    • DDPAC antibody
    • Disinhibition Dementia Parkinsonism Amyotrophy Complex antibody
    • FLJ31424 antibody
    • FTDP 17 antibody
    • FTDP17 antibody
    • G Protein Beta 1 Gamma 2 Subunit Interacting Factor 1 antibody
    • G protein beta1/gamma2 subunit interacting factor 1 antibody
    • MAPT antibody
    • MAPTL antibody
    • MGC134287 antibody
    • MGC138549 antibody
    • MGC156663 antibody
    • Microtubule Associated Protein Tau antibody
    • Microtubule associated protein tau isoform 4 antibody
    • Microtubule-associated protein tau antibody
    • MSTD antibody
    • Mtapt antibody
    • MTBT1 antibody
    • MTBT2 antibody
    • Neurofibrillary Tangle Protein antibody
    • Paired Helical Filament Tau antibody
    • Paired helical filament-tau antibody
    • PHF Tau antibody
    • PHF-tau antibody
    • PPND antibody
    • pTau antibody
    • RNPTAU antibody
    • TAU antibody
    • TAU_HUMAN antibody
    • Tauopathy and respiratory failure, included antibody
    see all

Anti-Tau (phospho S214) antibody images

  • ab10891 gave a positive result in ELISA against the immunising peptide (ab19123). This ELISA shows that ab10891 antibody has some cross-reactivity with the non-modified equivalent peptide (ab23425) when used at high concentrations. Not yet tested in other applications.
  • All lanes : Anti-Tau (phospho S214) antibody (ab10891) at 1/250 dilution

    Lane 1 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate
    Lane 2 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate with Human Tau (phospho S214) peptide (ab19123) at 1 µg/ml

    Lysates/proteins at 10 µg per lane.

    Secondary
    Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution

    Performed under reducing conditions.

    Predicted band size : 79 kDa
    Observed band size : 90 kDa (why is the actual band size different from the predicted?)


    Exposure time : 2 minutes
  • IHC image of Tau staining in human Alzheimer hippocampus formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab10891, 1µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

References for Anti-Tau (phospho S214) antibody (ab10891)

This product has been referenced in:
  • Wozniak MA  et al. Antivirals reduce the formation of key Alzheimer's disease molecules in cell cultures acutely infected with herpes simplex virus type 1. PLoS One 6:e25152 (2011). ICC ; African Green Monkey . Read more (PubMed: 22003387) »
  • Wozniak MA  et al. Alzheimer's disease-specific tau phosphorylation is induced by herpes simplex virus type 1. J Alzheimers Dis 16:341-50 (2009). ICC/IF ; Human . Read more (PubMed: 19221424) »

See all 2 Publications for this product

Product Wall

Abcam has not validated the combination of species/application used in this Abreview.
Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Mouse Tissue sections (Brain)
Specification Brain
Fixative Formaldehyde
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: Citric acid
Permeabilization No
Blocking step BSA as blocking agent for 10 minute(s) · Concentration: 1% · Temperature: 21°C
Username

Mr. Carl Hobbs

Verified customer

Submitted Nov 08 2010

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Human Tissue sections (Brain)
Specification Brain
Fixative Formaldehyde
Antigen retrieval step Heat mediated
Permeabilization Yes - Tween20
Blocking step Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 10% · Temperature: 25°C
Username

Mrs. Jianmin Chen

Verified customer

Submitted May 02 2008

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"